Feedback / Questions
TT125-802 - TOLREMO Therap
https://www.manilatimes.net/2025/06/04/tmt-newswire/globenewswire/tolremo-therapeutics-announces-tt125-802-is-the-first-cbpp300-bromodomain-inhibitor-to-show-clinical-activity-in-solid-tumors/2127195
Jun 4, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next